Treatment outcomes and secondary cancer incidence in young patients with hairy cell leukaemia Academic Article uri icon


MeSH Major

  • Leukemia, Hairy Cell
  • Neoplasms, Second Primary


  • Repeated therapy of hairy cell leukaemia (HCL) with treatments that have potential long-term toxicities has raised concerns regarding increased risk for younger patients. We compared clinical outcomes and disease complications in 63 patients with HCL aged ≤40 years at diagnosis with 268 patients >40 years treated at Memorial Sloan Kettering Cancer Center. The rate of complete remission following initial therapy was 87% and 83% (P = 0·71) and estimated 10-year overall survival was 100% and 82% (P = 0·25) in younger and older patients, respectively. Younger patients required therapy earlier and had a significantly shorter time between first and second therapy (median: 63 months vs. 145 months) (P = 0·008). Younger patients required significantly more lines of therapy during follow-up. The 10-year cumulative incidence of secondary malignancies in young and old patients was 0·205 and 0·287, respectively (P = 0·22). The incidence of secondary cancers in patients aged >40 years at diagnosis increased with the number of treatments for HCL (P = 0·018). These results highlight that young patients with HCL have shorter responses to treatment and require more lines of therapy to maintain disease control, while attaining similar long-term survival. This has implications in the design of future clinical trials given our findings that secondary malignancies increase with more chemotherapy exposure.

publication date

  • November 2016



  • Academic Article



  • eng

PubMed Central ID

  • PMC5539949

Digital Object Identifier (DOI)

  • 10.1111/bjh.14207

PubMed ID

  • 27351754

Additional Document Info

start page

  • 402

end page

  • 409


  • 175


  • 3